XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenue (Tables) | 6 Months Ended
--- | ---
Dec. 31, 2018
Revenue From Contract With Customer [Abstract] |
Composition of Total Revenue by Product and U.S versus Rest of World | The following tables present detail regarding the composition of the Company’s total revenue by product and U.S. versus rest of world, “RoW”:
|  | Three months ended December 31, |
|  | 2018 |  |  | 2017 |
(In millions) |  | U.S. |  |  | RoW |  |  | Total |  |  | U.S. |  |  | RoW |  |  | Total |
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing |  | $ | 123.4 |  |  | $ | 3.3 |  |  | $ | 126.7 |  |  | $ | 119.6 |  |  | $ | 2.6 |  |  | $ | 122.2 |
GeneSight |  |  | 24.0 |  |  |  | — |  |  |  | 24.0 |  |  |  | 31.7 |  |  |  | — |  |  |  | 31.7 |
Prenatal |  |  | 31.2 |  |  |  | — |  |  |  | 31.2 |  |  |  | — |  |  |  | — |  |  |  | — |
VectraDA |  |  | 11.8 |  |  |  | — |  |  |  | 11.8 |  |  |  | 11.1 |  |  |  | — |  |  |  | 11.1 |
Prolaris |  |  | 6.1 |  |  |  | — |  |  |  | 6.1 |  |  |  | 4.2 |  |  |  | — |  |  |  | 4.2 |
EndoPredict |  |  | 0.4 |  |  |  | 1.8 |  |  |  | 2.2 |  |  |  | 0.1 |  |  |  | 1.9 |  |  |  | 2.0 |
Other |  |  | 0.7 |  |  |  | 0.3 |  |  |  | 1.0 |  |  |  | 1.7 |  |  |  | 0.2 |  |  |  | 1.9 |
Total molecular diagnostic revenue |  |  | 197.6 |  |  |  | 5.4 |  |  |  | 203.0 |  |  |  | 168.4 |  |  |  | 4.7 |  |  |  | 173.1 |
Pharmaceutical and clinical service revenue |  |  | 8.2 |  |  |  | 5.6 |  |  |  | 13.8 |  |  |  | 8.9 |  |  |  | 5.9 |  |  |  | 14.8 |
Total revenue |  | $ | 205.8 |  |  | $ | 11.0 |  |  | $ | 216.8 |  |  | $ | 177.3 |  |  | $ | 10.6 |  |  | $ | 187.9 |
|  | Six months ended December 31, |
|  | 2018 |  |  | 2017 |
(In millions) |  | U.S. |  |  | RoW |  |  | Total |  |  | U.S. |  |  | RoW |  |  | Total |
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing |  | $ | 237.0 |  |  | $ | 6.1 |  |  | $ | 243.1 |  |  | $ | 234.2 |  |  | $ | 5.0 |  |  | $ | 239.2 |
GeneSight |  |  | 53.2 |  |  |  | — |  |  |  | 53.2 |  |  |  | 60.5 |  |  |  | — |  |  |  | 60.5 |
Prenatal |  |  | 49.3 |  |  |  | — |  |  |  | 49.3 |  |  |  | — |  |  |  | — |  |  |  | — |
VectraDA |  |  | 24.8 |  |  |  | — |  |  |  | 24.8 |  |  |  | 25.1 |  |  |  | — |  |  |  | 25.1 |
Prolaris |  |  | 12.3 |  |  |  | — |  |  |  | 12.3 |  |  |  | 8.1 |  |  |  | — |  |  |  | 8.1 |
EndoPredict |  |  | 0.7 |  |  |  | 3.9 |  |  |  | 4.6 |  |  |  | 0.1 |  |  |  | 3.7 |  |  |  | 3.8 |
Other |  |  | 4.4 |  |  |  | 0.3 |  |  |  | 4.7 |  |  |  | 3.5 |  |  |  | 0.3 |  |  |  | 3.8 |
Total molecular diagnostic revenue |  |  | 381.7 |  |  |  | 10.3 |  |  |  | 392.0 |  |  |  | 331.5 |  |  |  | 9.0 |  |  |  | 340.5 |
Pharmaceutical and clinical service revenue |  |  | 15.8 |  |  |  | 11.3 |  |  |  | 27.1 |  |  |  | 15.2 |  |  |  | 11.0 |  |  |  | 26.2 |
Total revenue |  | $ | 397.5 |  |  | $ | 21.6 |  |  | $ | 419.1 |  |  | $ | 346.7 |  |  | $ | 20.0 |  |  | $ | 366.7 |
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
|  | Six months ended |
|  | December 31, |
|  | 2018 |  |  | 2017 |
Deferred revenue - beginning balance |  | $ | 2.6 |  |  | $ | 2.6 |
Revenue recognized |  |  | (2.6 | ) |  |  | (10.3 | )
Prepayments |  |  | 2.4 |  |  |  | 11.1 |
Deferred revenue - Ending Balance |  | $ | 2.4 |  |  | $ | 3.4 |

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration